Table 4.
Crude rates per 1000 person years, 8-year cumulative risk, and crude and adjusted* hazard ratios for known prognostic breast cancer variables in relation to BMI
| Postmenopausal patients | ||||||||
|---|---|---|---|---|---|---|---|---|
| Variable | BMI | Persons | Cases | Person years | Crude rate per 1000 person years (95% CI) | 8-year cumulative risk (95% CI) |
Crude HR (95% CI) | Adjusted HR (95% CI) |
|
Tumor size < 20 mm |
< 25 | 16 553 | 228 | 121 000 | 1.88 (1.65–2.15) | 1.46% (1.27%-1.67%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 178 | 78 800 | 2.26 (1.94–2.62) | 1.70% (1.46%-1.97%) | 1.20 (0.99–1.46) | 1.20 (0.98–1.46) | |
| ≥ 30 | 4148 | 64 | 30 000 | 2.13 (1.64–2.72) | 1.63% (1.27%-2.08%) | 1.13 (0.86–1.49) | 1.20 (0.90–1.60) | |
|
Tumor size > 20 mm |
< 25 | 16 553 | 78 | 121 000 | 0.65 (0.51–0.81) | 0.50% (0.39%-0.62%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 63 | 78 800 | 0.80 (0.62–1.02) | 0.62% (0.48%-0.79%) | 1.24 (0.90–1.73) | 1.23 (0.88–1.72) | |
| ≥ 30 | 4148 | 27 | 30 000 | 0.90 (0.59–1.31) | 0.66% (0.45%-0.95%) | 1.39 (0.90–2.16) | 1.37 (0.87–2.16) | |
|
Nodal status Negative |
< 25 | 16 553 | 218 | 121 000 | 1.80 (1.57–2.06) | 1.40% (1.21%-1.60%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 184 | 78 800 | 2.34 (2.01–2.70) | 1.77% (1.52%-2.04%) | 1.30 (1.06–1.58) | 1.29 (1.06–1.58) | |
| ≥ 30 | 4148 | 58 | 30 000 | 1.93 (1.47–2.50) | 1.47% (1.12%-1.89%) | 1.07 (0.80–1.43) | 1.12 (0.83–1.51) | |
|
Nodal status Positive |
< 25 | 16 553 | 89 | 121 000 | 0.74 (0.59–0.91) | 0.57% (0.45%-0.71%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 57 | 78 800 | 0.72 (0.55–0.94) | 0.55% (0.42%-0.71%) | 0.98 (0.71–1.37) | 0.98 (0.70–1.37) | |
| ≥ 30 | 4148 | 35 | 30 000 | 1.17 (0.81–1.62) | 0.88% (0.62%-1.21%) | 1.58 (1.07–2.34) | 1.64 (1.09–2.48) | |
|
ER status Positive |
< 25 | 16 553 | 269 | 121 000 | 2.22 (1.97–2.51) | 1.71% (1.51%-1.93%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 211 | 78 800 | 2.68 (2.33–3.07) | 2.03% (1.76%-2.32%) | 1.20 (1.01–1.44) | 1.20 (1.00–1.44) | |
| ≥ 30 | 4148 | 85 | 30 000 | 2.83 (2.26–3.5) | 2.11% (1.70%-2.59%) | 1.27 (1.00–1.62) | 1.33 (1.03–1.71) | |
|
ER status Negative |
< 25 | 16 553 | 37 | 121 000 | 0.31 (0.22–0.42) | 0.25% (0.17%-0.35%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 24 | 78 800 | 0.31 (0.20–0.45) | 0.24% (0.16%-0.36%) | 1.00 (0.60–1.66) | 0.99 (0.59–1.67) | |
| ≥ 30 | 4148 | 7 | 30 000 | 0.23 (0.094–0.48) | 0.21% (0.09%-0.44%) | 0.76 (0.34–1.71) | 0.79 (0.34–1.81) | |
|
PR status Positive |
< 25 | 16 553 | 204 | 121 000 | 1.69 (1.46–1.93) | 1.31% (1.13%-1.51%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 162 | 78 800 | 2.06 (1.75–2.40) | 1.56% (1.33%-1.82%) | 1.22 (0.99–1.50) | 1.21 (0.99–1.50) | |
| ≥ 30 | 4148 | 75 | 30 000 | 2.50 (1.96–3.13) | 1.86% (1.48%-2.32%) | 1.48 (1.14–1.93) | 1.53 (1.16–2.02) | |
|
PR status Negative |
< 25 | 16 553 | 99 | 121 000 | 0.82 (0.67–1.00) | 0.63% (0.51%-0.77%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 70 | 78 800 | 0.89 (0.69–1.12) | 0.68% (0.53%-0.86%) | 1.08 (0.80–1.47) | 1.09 (0.80–1.48) | |
| ≥ 30 | 4148 | 17 | 30 000 | 0.57 (0.33–0.91) | 0.46% (0.27%-0.73%) | 0.69 (0.41–1.16) | 0.74 (0.44–1.25) | |
|
HER2 status Negative |
< 25 | 16 553 | 272 | 121 000 | 2.25 (1.99–2.53) | 1.75% (1.54%-1.97%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 209 | 78 800 | 2.65 (2.31–3.04) | 2.01% (1.75%-2.30%) | 1.18 (0.99–1.41) | 1.18 (0.98–1.41) | |
| ≥ 30 | 4148 | 83 | 30 000 | 2.76 (2.20–3.43) | 2.10% (1.68%-2.59%) | 1.23 (0.96–1.57) | 1.29 (1.00–1.66) | |
|
HER2 status Positive |
< 25 | 16 553 | 34 | 121 000 | 0.28 (0.20–0.39) | 0.21% (0.15%-0.29%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 29 | 78 800 | 0.37 (0.25–0.53) | 0.28% (0.19%-0.40%) | 1.31 (0.80–2.15) | 1.32 (0.80–2.18) | |
| ≥ 30 | 4148 | 10 | 30 000 | 0.33 (0.16–0.61) | 0.24% (0.13%-0.44%) | 1.18 (0.59–2.39) | 1.22 (0.59–2.53) | |
|
Histological grade 1/2 |
< 25 | 16 553 | 209 | 121 000 | 1.73 (1.50–1.98) | 1.33% (1.15%-1.54%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 171 | 78 800 | 2.17 (1.86–2.52) | 1.65% (1.42%-1.92%) | 1.26 (1.03–1.54) | 1.25 (1.02–1.54) | |
| ≥ 30 | 4148 | 67 | 30 000 | 2.23 (1.73–2.83) | 1.64% (1.28%-2.07%) | 1.29 (0.98–1.70) | 1.40 (1.05–1.86) | |
| Histological grade 3 | < 25 | 16 553 | 82 | 121 000 | 0.68 (0.54–0.84) | 0.53% (0.42%-0.66%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 58 | 78 800 | 0.74 (0.60–0.95) | 0.55% (0.43%-0.71%) | 1.09 (0.78–1.52) | 1.06 (0.75–1.49) | |
| ≥ 30 | 4148 | 20 | 30 000 | 0.67 (0.41–1.03) | 0.56% (0.35%-0.86%) | 0.98 (0.60–1.60) | 0.92 (0.56–1.54) | |
|
Ki67 Low |
< 25 | 16 553 | 161 | 121 000 | 1.33 (1.13–1.55) | 1.01% (0.86%-1.19%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 131 | 78 800 | 1.66 (1.39–1.97) | 1.28% (1.07%-1.53%) | 1.25 (0.99–1.57) | 1.26 (0.99–1.59) | |
| ≥ 30 | 4148 | 51 | 30 000 | 1.70 (1.26–2.23) | 1.25% (0.94%-1.63%) | 1.28 (0.93–1.75) | 1.37 (0.99–1.9) | |
|
Ki67 High |
< 25 | 16 553 | 138 | 121 000 | 1.14 (0.96–1.35) | 0.90% (0.75%-1.07%) | 1 (reference) | 1 (reference) |
| ≥ 25- < 30 | 10 809 | 99 | 78 800 | 1.26 (1.02–1.53) | 0.94% (0.76%-1.14%) | 1.10 (0.85–1.42) | 1.1 (0.85–1.43) | |
| ≥ 30 | 4148 | 39 | 30 000 | 1.30 (0.92–1.77) | 1.02% (0.73%-1.40%) | 1.14 (0.80–1.62) | 1.16 (0.80–1.67) | |
*Adjusted for reproductive factors (age at menarche, use of HRT and oral contraceptives, age at first child birth, number of births, co-medications (insulin, metformin, and statins), heredity, and life-style factors (smoking and alcohol)